Pfizer says supply chain challenges contributed to slashed target for COVID-19 vaccine doses in 2020
By Carl O'Donnell (Reuters) - Challenges in Pfizer Inc's supply chain for the raw materials used in its COVID-19 vaccine played a role in its decision to slash its 2020 production target, a Pfizer spokeswoman told Reuters. Pfizer has said in recent weeks that it anticipates producing 50 million doses of its COVID-19 vaccine this year
COVID-19 vaccine doses in 2020" src="https://images.firstpost.com/wp-content/uploads/reuters/12-2020/04/2020-12-03T214108Z_1_LYNXMPEGB21UY_RTROPTP_2_HEALTH-CORONAVIRUS-BRITAIN-VACCINE.jpg" alt="Pfizer says supply chain challenges contributed to slashed target for COVID19 vaccine doses in 2020" width="300" height="225" />
By Carl O'Donnell
(Reuters) - Challenges in Pfizer Inc's supply chain for the raw materials used in its COVID-19 vaccine played a role in its decision to slash its 2020 production target, a Pfizer spokeswoman told Reuters.
Pfizer has said in recent weeks that it anticipates producing 50 million doses of its COVID-19 vaccine this year. That is down from an earlier target of 100 million doses. Pfizer's vaccine relies on a two dose regimen, meaning 50 million doses is enough to inoculate 25 million people.
A company spokeswoman said the "scale-up of the raw material supply chain took longer than expected." She also cited later-than-expected results from Pfizer's clinical trial as a reason for the smaller number of doses expected to be produced by the end of 2020.
The spokeswoman added that the modifications to Pfizer's production lines are now complete and finished doses are being made at a rapid pace.
The Wall Street Journal was the first to report the news. It reported that an unnamed person directly involved in the development of the Pfizer vaccine said “some early batches of the raw materials failed to meet the standards," which caused production delays.
Pfizer applied in November for emergency authorization for its COVID-19 vaccine from U.S. regulators. U.S. officials said they expect its vaccine to get regulatory clearance this month. The U.S. government expects its first allocation of the vaccine to include 6.4 million doses, with more to follow.
Regulators in the U.K. have already authorized Pfizer's vaccine for use in that country.
(Reporting by Carl O'Donnell; Editing by David Gregorio and Stephen Coates)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By David Morgan and Susan Heavey WASHINGTON (Reuters) - President Donald Trump's fellow Republicans in the U.S. Senate on Friday overrode his veto for the first time in his nearly four years in office, pushing through a bill on defense spending against his strong objections 20 days before he leaves office. Meeting in a rare New Year's Day session, the Senate secured the two-thirds majority needed to override the veto with bipartisan support two days before a new Congress will be sworn in on Sunday.
By Douglas Busvine BERLIN (Reuters) - BioNTech is working flat out with partner Pfizer to boost production of their COVID-19 vaccine, its founders said, warning there would be gaps in supply until other vaccines were rolled out.
By Naveen Thukral and Gavin Maguire SINGAPORE (Reuters) -Global commodity markets ended 2020 on a strong note, with recovering demand and widespread stimulus packages buoying prices after a roller coaster ride caused by the global coronavirus pandemic.